ClinicalTrials.gg
CompletedNCT06310876Updated Jul 1, 2024

A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects

A Phase 1 interventional study of ABBV-CLS-7262 and ABBV-CLS-7262 in Healthy, sponsored by Calico Life Sciences LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by Calico Life Sciences LLC · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a randomized, blinded, placebo and active-controlled, 4-period, crossover design thorough QT/QTc (TQT) study to evaluate the effect of ABBV-CLS-7262 on cardiac repolarization in healthy adult subjects.

Read the detailed description

This is a randomized, blinded, placebo and active-controlled, 4-period, crossover study. The study will be double-blinded for ABBV-CLS-7262 (dose 1 or dose 2) and placebo regimens and open-label for moxifloxacin. 72 subjects are planned to be enrolled.

All subjects will receive a single oral dose of 4 different study treatments over 4 separate treatment periods, each separated by a washout period.

On Day 1 of each period, subjects will receive either ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg.

In each period, cardiodynamic ECGs will be collected pre-dose and for 24 hours post-dose and PK blood samples will be collected pre-dose and for 48 hours post-dose. Safety will be monitored throughout the study by repeated clinical and laboratory evaluations.

02

Conditions studied

  • Healthy

Keywords

  • TQT
  • Pharmacokinetics
03

In context

Lead sponsor

Calico Life Sciences LLC is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult volunteers in general good health.
  • Must voluntarily sign and date an , approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study-specific procedures.
  • Individuals between 18 and 55 years of age inclusive at the time of screening.
  • (BMI) is ≥ 18.0 to ≤ 29.9 kg/m2
  • All male subjects who are sexually active and not surgically sterilized must agree to use an acceptable method. Additionally, male subjects must agree to not donate sperm during the study until 30 days after the final dose of study drug.
  • All female subjects who are sexually active and of must agree to use a highly effective contraceptive method. Additionally, female subjects must agree to not donate eggs during the study and for 30 days after the final dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Subject who, in the opinion of the investigator, is incapable of completing study-required visits and procedures
  • Pregnant or breastfeeding.
  • Treatment with any other treatment within 30 days
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet

    Drug: ABBV-CLS-7262 · Drug: Placebo · Drug: Moxifloxacin 400mg

  • Experimental
    Sequence 2

    Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet

    Drug: ABBV-CLS-7262 · Drug: Placebo · Drug: Moxifloxacin 400mg

  • Experimental
    Sequence 3

    Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet

    Drug: ABBV-CLS-7262 · Drug: Placebo · Drug: Moxifloxacin 400mg

  • Experimental
    Sequence 4

    Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet

    Drug: ABBV-CLS-7262 · Drug: Placebo · Drug: Moxifloxacin 400mg

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of ABBV-CLS-7262 on the QTc interval in healthy adult subjects

    To evaluate the effect of ABBV-CLS-7262 on the QTc interval in healthy adult subjects.

    Time frame: Up to 24 hours

Secondary outcomes

  1. To evaluate the effects of ABBV-CLS-7262 on change in electrocardiogram (ECG) parameters

    ECG parameters include RR and PR interval, QRS duration and heart rate (HR).

    Time frame: Up to 24 hours

  2. To evaluate the sensitivity of QTc measurement using moxifloxacin

    To evaluate the sensitivity of QTc measurement using moxifloxacin.

    Time frame: Up to 24 hours

  3. To evaluate the effect of ABBV-CLS-7262 on T-wave morphology

    To evaluate the effect of ABBV-CLS-7262 on T-wave morphology.

    Time frame: Up to 24 hours

07

Study locations

1 site
  • AbbVie Clinical Pharmacology Research Unit (ACPRU)
    Grayslake, Illinois 60030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in May 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2024
First posted
Mar 15, 2024
StartActual
Mar 14, 2024
Primary completionActual
May 29, 2024
CompletionActual
Jun 26, 2024
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06310876
Lead sponsor
Calico Life Sciences LLC
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Mar 15, 2024
Start date
Mar 14, 2024
Primary completion
May 29, 2024
Completion
Jun 26, 2024
Last update
Jul 1, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fosigotifator sodium tromethamine

Start the discussion